At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INDP Indaptus Therapeutics, Inc.
Closed 03-12 16:00:00 EDT
0.8400
+0.0000
0.00%
盘后0.8120
-0.0280-3.33%
18:25 EDT
| High0.8500 | Low0.7601 | Vol7.35K |
| Open0.8400 | D1 Closing0.8400 | Amplitude10.70% |
| Mkt Cap11.86M | Tradable Cap9.54M | Total Shares14.12M |
| T/O6.00K | T/O Rate0.06% | Tradable Shares11.36M |
| P/B1.98 | ROE-139.60% | EPS-1.71 |
| 52wk High3.10 | 52wk Low0.7012 | P/E-0.49 |
| Dividend0.00 | Div.Yield0.00 | ROA-73.82% |
BRIEF-Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments
Reuters · 03-04
Indaptus Therapeutics expands patent portfolio in China, Japan, Israel
TIPRANKS · 03-04
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening Its Intellectual Property for Infectious Disease and Cancer Treatments
THOMSON REUTERS · 03-04
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
GlobeNewswire · 03-04
Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN
MT Newswires Live · 02-12
BRIEF-Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn
Reuters · 02-12
Indaptus Therapeutics Inc - Can Sell up to $20 Million of Stock to Yorkville
THOMSON REUTERS · 02-12
Indaptus Therapeutics Inc - Enters Equity Purchase Agreement With Ya Ii Pn
THOMSON REUTERS · 02-12
BRIEF-Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares
Reuters · 02-05
Indaptus Therapeutics Inc: Files Prospectus Relating to Proposed Resale by Selling Stockholders of up to 4.4 Mln Shares
THOMSON REUTERS · 02-05
Indaptus Therapeutics Says Health Canada Approves Start of Lead Asset Decoy20 Trial
MT Newswires Live · 02-05
Indaptus Therapeutics Receives Approval From Health Canada to Expand Clinical Trial of Decoy20
THOMSON REUTERS · 02-05
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
GlobeNewswire · 02-05
BRIEF-Indaptus Therapeutics Inc - Not In Compliance With Nasdaq Minimum Bid Price Requirements
Reuters · 01-31
Indaptus Therapeutics Inc - Not in Compliance With Nasdaq Minimum Bid Price Requirements
THOMSON REUTERS · 01-31
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS · 01-13
Indaptus Therapeutics- Combined Effective Purchase Price for Each Share & Warrants Is $1.065
THOMSON REUTERS · 01-13
Indaptus Therapeutics Inc - Gross Proceeds From Offering Expected to Be $2.25 Million
THOMSON REUTERS · 01-13
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire · 01-13
BRIEF-Indaptus Therapeutics Provides Year-End Review And Outlook For 2025
Reuters · 01-08
Introduction
Company Name.
Indaptus Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App